TORONTO and SAN FRANCISCO, March 17, 2026 /PRNewswire/ - Dalriada Drug Discovery ("Dalriada"), a partnered discovery organization supporting small-molecule programs from hit identification through ...

A new collaboration between EMBL's European Bioinformatics Institute (EMBL-EBI), Google DeepMind, NVIDIA, and Seoul National University has made millions of AI-predicted protein complex structures ...

The life science group Sartorius launches the new Octet ® R8e biolayer interferometry (BLI) system, providing researchers with its most advanced detection capabilities to date for real-time, ...

The collaboration targets disease areas where conventional small molecule drug discovery has faced challenges.

Scientists from the National University of Singapore (NUS) have developed a biochemical technique that captures fleeting ...

Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in ...

They build our bodies and orchestrate the molecular processes in cells that keep them healthy. They also present a wealth of targets for new medications. From everyday pain relievers to sophisticated ...

After three years of internal development, Expedition is building a generative AI platform for covalent drug discovery, supported by a $50M initial commitment from Flagship Pioneering Multi-target ...

Dalriada Drug Discovery (Dalriada), a partnered discovery organization supporting small-molecule programmes from hit identification through lead optimization, and Topos Bio (Topos), an AI-native ...